Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: ALD403 in Chronic Migraine
NCT02985398Phase 3Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eptinezumab in chronic migraine, sponsored by Alder Biopharmaceuticals. Primary endpoints: Number of Participants With Any Treatment Emergent Adverse Events at 104 Weeks, Number of Participants With a Clinically Significant Electrocardiogram at 104 Weeks and 3 more. Started Dec 2016; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02985398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985398.